We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Operation Warp Speed (OWS)’s chief adviser Moncef Slaoui submitted his resignation Tuesday but said he will stay on in that role for 30 days after Jan. 21 to support the incoming administration. Read More
A last-minute proposal by the outgoing Trump administration would weaken one of the few tools the federal government has to directly reduce the price of new prescription drugs. Read More
HHS announced yesterday it will no longer stockpile millions of COVID-19 vaccine doses held to ensure Americans receive their second shot, but will distribute them immediately and give states two weeks to comply with new federal rules for dose allocation. Read More
The ongoing rifts between HHS and the FDA continued this week with confusion surrounding the department’s selection of James Lawrence as the agency’s chief counsel, just hours after FDA Commissioner Stephen Hahn announced a different pick to agency staff. Read More
AstraZeneca (AZ) has filed for EU approval of its COVID-19 vaccine and a conditional marketing authorization is expected in late January following a Jan. 29 meeting of the European Medicines Agency’s (EMA) expert panel on human medicines. Read More
The 1,246-page trade agreement also includes mutual commitments on intellectual property, including patents, trademarks and designs, and unregistered rights, such as copyright, trade secrets and unregistered designs. Read More
Pfizer/BioNTech’s COVID-19 vaccine should ideally be given in two doses 21 to 28 days apart, but due to ongoing shortages, an interval of up to 42 days is acceptable, the World Health Organization (WHO) said Friday. Read More
The Center for Drug Evaluation and Research (CDER) is set to reorganize its Office of Generic Drugs (OGD) to help keep up with the high volume of generic drug applications. Read More
Bristol Myers Squibb has withdrawn the U.S. indication for its blockbuster drug Opdivo (nivolumab) for treatment of small cell lung cancer, following disappointing clinical trial results. Read More
A federal appeals court ruling last year against Teva Pharmaceuticals threatens other generic drugmakers, according to an amicus brief filed Dec. 22 by a roll call of professors of law, economics, business, health and medicine. Read More
The long-time director of the FDA’s Center for Drug Evaluation and Research (CDER), Janet Woodcock, who stepped aside last year to head the therapeutics arm of the U.S. government’s Operation Warp Speed (OWS) initiative, is taking up a new role as principal medical adviser to FDA Commissioner Stephen Hahn. Read More